An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works

BEDTools: a flexible suite of utilities for comparing genomic features

Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437 · see citing works

Model-based Analysis of ChIP-Seq (MACS)

Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386 · see citing works

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy

Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,949 · see citing works

Integrative analysis of 111 reference human epigenomes

Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368 · see citing works

A bivalent chromatin structure marks key developmental genes in embryonic stem cells

Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361 · see citing works

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · cited 1× · see citing works

Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences

Goecks, J., Nekrutenko, A., Taylor, J., & The Galaxy Team (2010) · Genome biology · doi:10.1186/gb-2010-11-8-r86 · Cited by 3,437 · see citing works

A landscape of driver mutations in melanoma

Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · see citing works

Polycomb complexes repress developmental regulators in murine embryonic stem cells

Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,518 · see citing works

BRAFE600-associated senescence-like cell cycle arrest of human naevi

Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · see citing works

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · see citing works

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,670 · see citing works

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · see citing works

Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitionsPreprint

Bracken, A. P., Dietrich, N., Pasini, D., Hansen, K. H., & Helin, K. (2006) · Genes & Development · doi:10.1101/gad.381706 · Cited by 1,258 · see citing works

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191 · see citing works

BrafV600E cooperates with Pten loss to induce metastatic melanoma

Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189 · see citing works

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Chapuy, B., Sougnez, C. L., Cruz‐Gordillo, P., Knoechel, B., Asmann, Y. W., Slager, S. L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121343109 · Cited by 977 · see citing works

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

Pasqualucci, L., Dominguez-Sola, D., Chiarenza, A., Fabbri, G., Grunn, A., Trifonov, V., Kasper, L. H., Lerach, S., Tang, H., Ma, J., et al. (2011) · Nature · doi:10.1038/nature09730 · Cited by 949 · see citing works

EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation

Béguelin, W., Popovic, R., Teater, M. R., Jiang, Y., Bunting, K. L., Rosen, M., Shen, H., Yang, S. N., Wang, L., Ezponda, T., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.011 · Cited by 854 · see citing works

The Polycomb group proteins bind throughout the <i>INK4A-ARF</i> locus and are disassociated in senescent cells

Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Mönch, K., Minucci, S., Porse, B. T., Marine, J.-C., et al. (2007) · Genes &amp; Development · doi:10.1101/gad.415507 · Cited by 850 · see citing works

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Scott, M. P., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 794 · see citing works

Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene.Preprint

van der Lugt, N. M. T., Domen, J., Linders, K., van ROON, M. A., Robanus-Maandag, E. C., Riele, H. T., van der Valk, M., Deschamps, J., Sofroniew, M. V., & van Lohuizen, M. (1994) · Genes & Development · doi:10.1101/gad.8.7.757 · Cited by 781 · see citing works

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 754 · see citing works

B lymphocyte-specific, Cre-mediated mutagenesis in mice

Rickert, R. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.6.1317 · Cited by 724 · see citing works

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 691 · see citing works

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Bitler, B. G., Aird, K. M., Гарипов, А. Р., Li, H., Amatangelo, M. D., Kossenkov, A. V., Schultz, D., Liu, Q., Shih, I., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 683 · see citing works

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

Kondo, Y., Shen, L., Cheng, A. S. L., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Kwabi‐Addo, B., et al. (2008) · Nature Genetics · doi:10.1038/ng.159 · Cited by 618 · see citing works

Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement

Su, I.-H., Basavaraj, A., Krutchinsky, A. N., Hobert, O., Ullrich, A., Chait, B. T., & Tarakhovsky, A. (2002) · Nature Immunology · doi:10.1038/ni876 · Cited by 614 · see citing works

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation

Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 609 · see citing works

Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia

Ntziachristos, P., Tsirigos, A., Vlierberghe, P. V., Nedjic, J., Trimarchi, T., Flaherty, M. S., Ferrés-Marcó, D., Ros, V. G. D., Tang, Z., Siegle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2651 · Cited by 528 · see citing works

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 493 · see citing works

A new mouse model to explore the initiation, progression, and therapy of BRAF V600E -induced lung tumorsPreprint

Dankort, D. L., Filenova, E., Collado, M., Serrano, M., Jones, K. D., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 476 · see citing works

An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1

Konze, K. D., Ma, A., Li, F., Baršytė-Lovejoy, D., Parton, T., MacNevin, C. J., Liu, F., Gao, C., Huang, X., Kuznetsova, E., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb400133j · Cited by 450 · see citing works

Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2

Jiao, L., & Liu, X. (2015) · Science · doi:10.1126/science.aac4383 · Cited by 402 · see citing works

MYC stimulates EZH2 expression by repression of its negative regulator miR-26a

Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F. E., Möller, P., Stilgenbauer, S., Pollack, J. R., & Wirth, T. (2008) · Blood · doi:10.1182/blood-2008-03-147645 · Cited by 394 · see citing works

Loss of BAP1 function leads to EZH2-dependent transformation

LaFave, L. M., Béguelin, W., Koche, R. P., Teater, M. R., Spitzer, B. G., Chramiec, A. G., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3947 · Cited by 381 · see citing works

The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion

Kamminga, L. M., Bystrykh, L. V., de Boer, A., Houwer, S., Douma, J., Weersing, E., Dontje, B., & de Haan, G. (2006) · Blood · doi:10.1182/blood-2005-09-3585 · Cited by 376 · see citing works

AID is required for germinal center–derived lymphomagenesis

Pasqualucci, L., Bhagat, G., Janković, M., Compagno, M., Smith, P. M., Muramatsu, M., Honjo, T., Morse, H. C., Nussenzweig, M. C., & Dalla‐Favera, R. (2007) · Nature Genetics · doi:10.1038/ng.2007.35 · Cited by 376 · see citing works

Polycomb protein Ezh2 regulates pancreatic β-cell <i>Ink4a/Arf</i> expression and regeneration in diabetes mellitus

Chen, H., Gu, X., Su, I.-H., Bottino, R., Contreras, J. L., Tarakhovsky, A., & Kim, S. K. (2009) · Genes &amp; Development · doi:10.1101/gad.1742509 · Cited by 366 · see citing works

COSMIC 2005

Forbes, S. A., Clements, J., Dawson, E., Bamford, S., Webb, T., Doǧan, A., Flanagan, A. M., Teague, J. W., Wooster, R., Futreal, P. A., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602928 · Cited by 327 · see citing works

pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor genePreprint

Kotake, Y., Cao, R., Viatour, P., Sage, J., Zhang, Y., & Xiong, Y. (2007) · Genes & Development · doi:10.1101/gad.1499407 · Cited by 314 · see citing works

ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity

Young, M. D., Willson, T. A., Wakefield, M. J., Trounson, E., Hilton, D. J., Blewitt, M. E., Oshlack, A., & Majewski, I. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr416 · Cited by 309 · see citing works

A Correction to the Research Article Titled: “Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death” by R. Xu, N. Sen, B. D. Paul, A. M. Snowman, F. Rao, M. S. Vandiver, J. Xu, S. H. Snyder

(2013) · Science Signaling · doi:10.1126/scisignal.6273er1 · Cited by 242 · see citing works

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma

Visser, H. P. J., Gunster, M. J., Kluin‐Nelemans, H. C., Manders, E. M. M., Raaphorst, F. M., Meijer, C. J. L. M., Willemze, R., & Otte, A. P. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02641.x · Cited by 236 · see citing works

Functional antagonism of the polycomb-group genes eed and Bmi1 in hemopoietic cell proliferation

Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., & Sauvageau, G. (1999) · Genes &amp; Development · doi:10.1101/gad.13.20.2691 · Cited by 219 · see citing works

Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma

Burd, C. E., Liu, W., Huynh, M. V., Waqas, M. A., Gillahan, J. E., Clark, K. S., Fu, K., Martin, B. L., Jeck, W. R., Souroullas, G. P., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0729 · Cited by 214 · see citing works

Cell cycle activation by c-myc in a Burkitt lymphoma model cell line

Pajic, A., Spitkovsky, D., Christoph, B., Kempkes, B., Schuhmacher, M., Staege, M. S., Brielmeier, M., Ellwart, J. W., Kohlhuber, F., Bornkamm, G. W., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000915)87:6 · Cited by 204 · see citing works

Coexpression of BMI-1 and EZH2 Polycomb Group Genes in Reed-Sternberg Cells of Hodgkin’s Disease

Raaphorst, F. M., van Kemenade, F. J., Blokzijl, T., Fieret, E. J. H., Hamer, K. M., Satijn, D. P. E., Otte, A. P., & Meijer, C. J. L. M. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64583-x · Cited by 166 · see citing works

Characterization of melanocyte‐specific inducible Cre recombinase transgenic mice

Bosenberg, M., Muthusamy, V., Curley, D. P., Wang, Z., Hobbs, C., Nelson, B., Nogueira, C., Horner, J. W., DePinho, R. A., & Chin, L. (2006) · genesis · doi:10.1002/dvg.20205 · Cited by 160 · see citing works

Somatic p16INK4a loss accelerates melanomagenesis

Monahan, K. B., Rozenberg, G. I., Krishnamurthy, J., Johnson, S. M., Liu, W., Bradford, M. K., Horner, J. W., DePinho, R. A., & Sharpless, N. E. (2010) · Oncogene · doi:10.1038/onc.2010.314 · Cited by 72 · see citing works

Utilization of Pathway Signatures to Reveal Distinct Types of B Lymphoma in the Eμ- myc Model and Human Diffuse Large B-Cell Lymphoma

Mori, S., Rempel, R. E., Chang, J. T., Yao, G., Lagoo, A. S., Potti, A., Bild, A. H., & Nevins, J. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1329 · Cited by 71 · see citing works

Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer

Zuo, T., Liu, T.-M., Lan, X., Weng, Y., Shen, R. Z., Gu, F., Huang, Y., Liyanarachchi, S., Deatherage, D. E., Hsu, P.-Y., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3573 · Cited by 63 · see citing works

A Transgenic Mouse Model of Plasma Cell Malignancy Shows Phenotypic, Cytogenetic, and Gene Expression Heterogeneity Similar to Human Multiple Myeloma

Boylan, K. L. M., Gosse, M. A., Staggs, S. E., Janz, S., Grindle, S. M., Kansas, G. S., & Ness, B. G. V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3699 · Cited by 47 · see citing works

The roles of DNA, RNA and histone methylation in ageing and cancer

Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549 · see citing works

Epigenetic regulation of brain region-specific microglia clearance activity

Ayata, P., Badimon, A., Strasburger, H. J., Duff, M. K., Montgomery, S. E., Loh, Y.-H. E., Ebert, A., Pimenova, A. A., Ramirez, B. R., Chan, A. T., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0192-3 · Cited by 460 · see citing works

Maintaining cell identity: PRC2-mediated regulation of transcription and cancer

Comet, I. V., Riising, E. M., Leblanc, B., & Helin, K. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.83 · Cited by 428 · see citing works

Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

Gan, L., Yang, Y., Li, Q., Feng, Y., Liu, T., & Guo, W.-J. (2018) · Biomarker Research · doi:10.1186/s40364-018-0122-2 · Cited by 428 · see citing works

The language of chromatin modification in human cancers

Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00357-x · Cited by 406 · see citing works

The roles of Polycomb repressive complexes in mammalian development and cancer

Piunti, A., & Shilatifard, A. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00341-1 · Cited by 382 · see citing works

Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis

Hanniford, D., Ulloa-Morales, A. J., Karz, A., Berzoti-Coelho, M. G., Moubarak, R. S., Sánchez‐Sendra, B., Kloetgen, A., Dávalos, V., Imig, J., Wu, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.007 · Cited by 345 · see citing works

Inhibitors of Protein Methyltransferases and Demethylases

Kanıskan, H. Ü., Martini, M. L., & Jin, J. J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00801 · Cited by 320 · see citing works

CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis

Huang, Y., Cai, K., Xu, P., Wang, L., Huang, C., Fang, Y., Cheng, S., Sun, X., Liu, F., Huang, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00437-8 · Cited by 228 · see citing works

Targeting EZH2 in cancer therapy

Yamagishi, M., & Uchimaru, K. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000390 · Cited by 224 · see citing works

Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancerPreprint

Bracken, A. P., Brien, G. L., & Verrijzer, C. P. (2019) · Genes & Development · doi:10.1101/gad.326066.119 · Cited by 192 · see citing works

Epigenetics of hematopoiesis and hematological malignanciesPreprint

Hu, D., & Shilatifard, A. (2016) · Genes & Development · doi:10.1101/gad.284109.116 · Cited by 167 · see citing works

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response

Béguelin, W., Teater, M. R., Meydan, C., Hoehn, K. B., Phillip, J. M., Soshnev, A. A., Venturutti, L., Rivas, M. A., Calvo, M. T., Gutierrez, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.004 · Cited by 161 · see citing works

Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Sesques, P., & Johnson, N. A. (2016) · Blood · doi:10.1182/blood-2016-02-636316 · Cited by 164 · see citing works

EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains

Collier, M. D., Sungalee, S., Zufferey, M., Tavernari, D., Katanayeva, N., Battistello, E., Mina, M., Douglass, K. M., Rey, T., Raynaud, F., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0338-y · Cited by 147 · see citing works

Mechanisms of Polycomb group protein function in cancer

Parreno, V., Martinez, A., & Cavalli, G. (2022) · Cell Research · doi:10.1038/s41422-021-00606-6 · Cited by 147 · see citing works

Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor

Honma, D., Kanno, O., Watanabe, J., Kinoshita, J., Hirasawa, M., Nosaka, E., Shiroishi, M., Takizawa, T., Yasumatsu, I., Horiuchi, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13326 · Cited by 144 · see citing works

Chromatin modifying gene mutations in follicular lymphoma

Green, M. R. (2017) · Blood · doi:10.1182/blood-2017-08-737361 · Cited by 141 · see citing works

Methylation across the central dogma in health and diseases: new therapeutic strategies

Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 147 · see citing works

Engaging chromatin: PRC2 structure meets function

Chammas, P., Mocavini, I., & Croce, L. D. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0615-2 · Cited by 138 · see citing works

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation

Zingg, D., Debbache, J., Peña‐Hernández, R., Antunes, A. T., Schaefer, S. M., Cheng, P. F., Zimmerli, D., Häusel, J., Calçada, R. R., Tuncer, E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.001 · Cited by 136 · see citing works

Advances in targeted therapy for malignant lymphoma

Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 140 · see citing works

Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene

Fontanals-Cirera, B., Hasson, D., Vardabasso, C., Micco, R. D., Agrawal, P. K., Chowdhury, A. H., Gantz, M., de Pablos-Aragoneses, A., Morgenstern, A., Wu, P., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.004 · Cited by 129 · see citing works

Epigenetics of malignant melanoma

Moran, B., Silva, R., Perry, A. S., & Gallagher, W. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.006 · Cited by 129 · see citing works

Spitz melanoma is a distinct subset of spitzoid melanoma

Raghavan, S. S., Peternel, S., Mully, T. W., North, J. P., Pincus, L. B., LeBoit, P. E., McCalmont, T. H., Bastian, B. C., & Yeh, I. (2020) · Modern Pathology · doi:10.1038/s41379-019-0445-z · Cited by 121 · see citing works

Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds

Fioravanti, R., Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2018) · The Chemical Record · doi:10.1002/tcr.201800091 · Cited by 119 · see citing works

G-tract RNA removes Polycomb repressive complex 2 from genes

Beltran-Nebot, M., Tavares, M., Justin, N., Khandelwal, G., Ambrose, J. C., Foster, B. M., Worlock, K. B., Tvardovskiy, A., Kunzelmann, S., Herrero, J., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0293-z · Cited by 111 · see citing works

Design principles of 3D epigenetic memory systems

Owen, J. A., Osmanović, D., & Mirny, L. A. (2023) · Science · doi:10.1126/science.adg3053 · Cited by 104 · see citing works

EZH2 alterations in follicular lymphoma: biological and clinical correlations

Huet, S., Xerri, L., Tesson, B. M., Mareschal, S., Taix, S., Mescam-Mancini, L., Sohier, E., Carrère, M., Lazarovici, J., Casasnovas, O., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.32 · Cited by 101 · see citing works

Orchestration of H3K27 methylation: mechanisms and therapeutic implication

Pan, M., Hsu, M., Chen, L., & Hung, W. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2596-8 · Cited by 99 · see citing works

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications

Li, B., & Chng, W. J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0814-6 · Cited by 99 · see citing works

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling

Strub, T., Ghiraldini, F. G., Carcamo, S., Li, M., Wroblewska, A., Singh, R., Goldberg, M. S., Hasson, D., Wang, Z., Gallagher, S. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05966-z · Cited by 93 · see citing works

Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors

Han, M., Jia, L., Lv, W., Wang, L., & Cui, W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00194 · Cited by 94 · see citing works

EZH2 inhibits NK cell–mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner

Bugide, S., Gupta, R., Green, M. R., & Wajapeyee, N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102718118 · Cited by 85 · see citing works

Roles of H3K27me2 and H3K27me3 Examined during Fate Specification of Embryonic Stem Cells

Juan, A. H., Wang, S., Ko, K. D., Zare, H., Tsai, P.-F., Feng, X., Vivanco, K. O., Ascoli, A. M., Gutierrez-Cruz, G., Krebs, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.087 · Cited by 77 · see citing works

Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy

Kgatle, M. M., Kalla, A. A., Islam, M. M., Sathekge, M. M., & Moorad, R. (2016) · Prostate Cancer · doi:10.1155/2016/5653862 · Cited by 81 · see citing works

Indicators of responsiveness to immune checkpoint inhibitors

Shields, B. D., Mahmoud, F. A., Taylor, E. M., Byrum, S. D., Sengupta, D., Koss, B. S., Baldini, G., Ransom, S. C., Cline, K., Mackintosh, S. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01000-2 · Cited by 80 · see citing works

Ezh2 Inhibition by Tazemetostat: Mechanisms of Action, Safety and Efficacy in Relapsed/refractory Follicular Lymphoma

Julia, E., & Salles, G. (2021) · Future Oncology · doi:10.2217/fon-2020-1244 · Cited by 79 · see citing works

Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors

Pekmezci, M., Cuevas-Ocampo, A. K., Perry, A., & Horvai, A. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.97 · Cited by 79 · see citing works

Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitors

Li, C., Wang, Y., Gong, Y., Zhang, T., Huang, J., Tan, Z. W., & Xue, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01045-1 · Cited by 76 · see citing works

Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis

Kato, S., Weng, Q. Y., Insco, M. L., Chen, K. Y., Muralidhar, S., Poźniak, J., Diaz, J. M. S., Drier, Y., Nguyen, N. T., Lo, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0532 · Cited by 74 · see citing works

Structural basis for inactivation of PRC2 by G-quadruplex RNA

Song, J., Gooding, A. R., Hemphill, W. O., Love, B. D., Robertson, A., Yao, L., Zon, L. I., North, T. E., Kasinath, V., & Cech, T. R. (2023) · Science · doi:10.1126/science.adh0059 · Cited by 73 · see citing works

Epigenetic regulation of tumor immunity

Pang, L., Zhou, F., Liu, Y., Ali, H. A., Khan, F., Heimberger, A. B., & Chen, P. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178540 · Cited by 74 · see citing works

The “ART” of Epigenetics in Melanoma: From histone “Alterations, to Resistance and Therapies”

Strub, T., Ballotti, R., & Bertolotto, C. (2020) · Theranostics · doi:10.7150/thno.36218 · Cited by 71 · see citing works

Structure of the PRC2 complex and application to drug discovery

Shi, Y., Wang, X., Zhuang, Y., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.7 · Cited by 70 · see citing works

The role of EZH1 and EZH2 in development and cancer

Lee, S. H., Li, Y., Kim, H., Eum, S., Park, K., & Lee, C. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.12.174 · Cited by 65 · see citing works

Dysregulation of histone methyltransferases in breast cancer – Opportunities for new targeted therapies?

Michalak, E. M., & Visvader, J. E. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.003 · Cited by 65 · see citing works

The Multiple Facets of PRC2 Alterations in Cancers

Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 62 · see citing works

Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity

Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 57 · see citing works

Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer

Koschmann, C. J., Núñez, F. J., Mendez, F., Brosnan‐Cashman, J. A., Meeker, A. K., Lowenstein, P. R., & Castro, M. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2301 · Cited by 59 · see citing works

ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer

Zhang, P., Xiao, Z., Wang, S., Zhang, M., Wei, Y., Hang, Q., Kim, J., Yao, F., Rodriguez‐Aguayo, C., Ton, B. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.078 · Cited by 61 · see citing works

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia

Ariës, I. M., Bodaar, K., Karim, S., Chonghaile, T. N., Hinze, L., Burns, M., Pfirrmann, M., Degar, J., Landrigan, J., Balbach, S. T., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180570 · Cited by 60 · see citing works

Epigenetic determinants of metastasis

Patel, S. A., & Vanharanta, S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.008 · Cited by 56 · see citing works

Polycomb repressive complexes in hematological malignancies

Iwama, A. (2017) · Blood · doi:10.1182/blood-2017-02-739490 · Cited by 55 · see citing works

Epigenetic dysregulation in hepatocellular carcinoma: an up‐to‐date review

Nakamura, M., Chiba, T., Kanayama, K., Kanzaki, H., Saito, T., Kusakabe, Y., & Kato, N. (2018) · Hepatology Research · doi:10.1111/hepr.13250 · Cited by 55 · see citing works

Long Non-coding RNA LINC-PINT Suppresses Cell Proliferation and Migration of Melanoma via Recruiting EZH2

Xu, Y., Wang, H., Li, F., Heindl, L. M., He, X., Yu, J., Yang, J., Ge, S., Ruan, J., Jia, R., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00350 · Cited by 53 · see citing works

Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer

Fowle-Grider, R., Rowles, J. L., Shen, I., Wang, Y., Schwaiger-Haber, M., Dunham, A. J., Jayachandran, K., Inkman, M. J., Zahner, M. C., Naser, F. J., et al. (2024) · Nature · doi:10.1038/s41586-024-08258-3 · Cited by 53 · see citing works

Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies

Sashida, G., & Iwama, A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2124-x · Cited by 52 · see citing works

β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2

Cheng, H., Ge, X., Zhuo, S., Gao, Y., Zhu, B., Zhang, J., Shang, W., Xu, D., Ge, W., & Shi, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01413 · Cited by 50 · see citing works

Drugging histone methyltransferases in cancer

Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 49 · see citing works

Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer

Anwar, T., Gonzalez, M. E., & Kleer, C. G. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.01.013 · Cited by 49 · see citing works

A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation

Wang, J., Park, K., Yu, X., Gong, W., Earp, H. S., Wang, G. G., Jin, J. J., & Cai, L. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac861 · Cited by 46 · see citing works

Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies

Nakagawa, M., & Kitabayashi, I. (2018) · Cancer Science · doi:10.1111/cas.13655 · Cited by 46 · see citing works

Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy?

Jangal, M., Lebeau, B., & Witcher, M. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1627329 · Cited by 45 · see citing works

Calcitonin gene-related peptide regulates spinal microglial activation through the histone H3 lysine 27 trimethylation via enhancer of zeste homolog-2 in rats with neuropathic pain

An, Q., Sun, C., Li, R., Chen, S., Gu, X., An, S., & Wang, Z. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02168-1 · Cited by 46 · see citing works

Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer

Chu, L., Qu, Y.-X., An, Y., Hou, L., Li, J., Li, W., Fan, G., Song, B., Li, E., Zhang, L., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04601-6 · Cited by 45 · see citing works

New Approaches to Targeted Therapy in Melanoma

Fernandez, M. F., Choi, J. S., & Sosman, J. A. (2023) · Cancers · doi:10.3390/cancers15123224 · Cited by 44 · see citing works

Non-canonical functions of EZH2 in cancer

Zimmerman, S. M., Lin, P. N., & Souroullas, G. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233953 · Cited by 43 · see citing works

Exploiting epigenetic vulnerabilities in solid tumors: Novel therapeutic opportunities in the treatment of SWI/SNF-defective cancers

Chabanon, R. M., Morel, D., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.018 · Cited by 43 · see citing works

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma

Palamaris, K., Moutafi, M. K., Gakiopoulou, H., & Theocharis, S. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073660 · Cited by 42 · see citing works

Ezh2 loss propagates hypermethylation at T cell differentiation–regulating genes to promote leukemic transformation

Wang, C., Oshima, M., Sato, D., Matsui, H., Kubota, S., Aoyama, K., Nakajima‐Takagi, Y., Koide, S., Matsubayashi, J., Mochizuki‐Kashio, M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94645 · Cited by 38 · see citing works

Targeted in vivo epigenome editing of H3K27me3

Fukushima, H. S., Takeda, H., & Nakamura, R. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0263-z · Cited by 38 · see citing works

The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor

Zhang, X., Murray, B., Mo, G., & Shern, J. F. (2020) · Genes · doi:10.3390/genes11030287 · Cited by 40 · see citing works

A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis

Dhar, S., Gadd, S., Patel, P. A., Vaynshteyn, J., Raju, G. P., Hashizume, R., Brat, D. J., & Becher, O. J. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01336-5 · Cited by 38 · see citing works

Smoker extracellular vesicles influence status of human bronchial epithelial cells

Héliot, A., Landkocz, Y., Saint-Georges, F. R., Gosset, P., Billet, S., Shirali, P., Courcot, D., & Martin, P. J. (2016) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2016.12.010 · Cited by 38 · see citing works

Disruption of YY1-EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development

Cheng, Y., Li, G., Wang, W., Sun, Y., Zhang, Y., Chen, Z., Stovall, D. B., Li, D., Shi, J., & Sui, G. (2021) · Cancers · doi:10.3390/cancers13102402 · Cited by 37 · see citing works

Transcriptional regulators and alterations that drive melanoma initiation and progression

Gupta, R., Janoštiak, R., & Wajapeyee, N. (2020) · Oncogene · doi:10.1038/s41388-020-01490-x · Cited by 36 · see citing works

A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia

Ren, Z., Kim, A., Huang, Y., Pi, W., Gong, W., Yu, X., Qi, J., Jin, J. J., Cai, L., Roeder, R. G., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122940119 · Cited by 35 · see citing works

Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer

Xie, Y., Xiao, D., Li, D., Peng, M., Peng, W., Duan, H., & Yang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1441222 · Cited by 34 · see citing works

Epigenetic Alterations in Parathyroid Cancers

Verdelli, C., & Corbetta, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020310 · Cited by 32 · see citing works

Whole‐exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells

Hartman, M. L., Sztiller-Sikorska, M., & Czyż, M. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22953 · Cited by 32 · see citing works

The Yin and Yang of cancer genes

Bashyam, M. D., Animireddy, S., Bala, P., Naz, A., & George, S. A. (2019) · Gene · doi:10.1016/j.gene.2019.04.025 · Cited by 32 · see citing works

Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation

Peeters, J. G. C., Silveria, S. L., Özdemir, M., Ramachandran, S., & DuPage, M. J. P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114724 · Cited by 30 · see citing works

From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy

Karagianni, P., Giannouli, S., & Voulgarelis, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126321 · Cited by 32 · see citing works

Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer

Angus, S. P., Zawistowski, J. S., & Johnson, G. L. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052954 · Cited by 32 · see citing works

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma

Munakata, W., Shirasugi, Y., Tobinai, K., Onizuka, M., Makita, S., Suzuki, R., Maruyama, D., Kawai, H., Izutsu, K., Nakanishi, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14822 · Cited by 30 · see citing works

Polycomb Directed Cell Fate Decisions in Development and Cancer

German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 36 · see citing works

The Complex Role of EZH2 in the Tumor Microenvironment: Opportunities and Challenges for Immunotherapy Combinations

Qiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0072 · Cited by 29 · see citing works

Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia

Wang, J., He, N., Wang, R., Tian, T., Han, F., Zhong, C., Zhang, C., Hua, M., Ji, C., & Ma, D. (2020) · Scientific Reports · doi:10.1038/s41598-020-59365-w · Cited by 28 · see citing works

Systematic review and meta‐analysis of genomic alterations in acral melanoma

Broit, N., Johansson, P. A., Rodgers, C. B., Walpole, S., Hayward, N. K., & Pritchard, A. L. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13034 · Cited by 28 · see citing works

Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling

Xu, T., Xu, M., Zhu, W., Chen, C. Z., Zhang, Q., Zheng, W., & Huang, R. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01372 · Cited by 29 · see citing works

Chemical biology and pharmacology of histone lysine methylation inhibitors

Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 27 · see citing works

EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition

Romero, P., Richart, L., Aflaki, S., Petitalot, A., Burton, M., Michaud, A., Masliah‐Planchon, J., Kuhnowski, F., Cam, S. L., Baliñas-Gavira, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47701-x · Cited by 26 · see citing works

Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology

Tan, W. Y., Nagabhyrava, S., Ang-Olson, O., Das, P., Ladel, L., Sailo, B., He, L., Sharma, A. R., & Ahuja, N. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070390 · Cited by 27 · see citing works

Methylation alterations and advance of treatment in lymphoma

Liu, M.-K., Sun, X.-J., Gao, X.-D., Qian, Y., Wang, L., & Zhao, W.-L. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4970 · Cited by 26 · see citing works

Characterizing crosstalk in epigenetic signaling to understand disease physiology

Lempiäinen, J. K., & Garcia, B. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220550 · Cited by 26 · see citing works

Novel epigenetic therapies in hematological malignancies: Current status and beyond

Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25 · see citing works

Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas

Morschhauser, F., Salles, G., Batlevi, C. L., Tilly, H., Chaidos, A., Phillips, T., Burke, J. M., & Melnick, A. M. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100988 · Cited by 25 · see citing works

MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer

Soto‐Feliciano, Y. M., Zhu, C., Morris, J. P., Huang, C., Koche, R. P., Ho, Y.-J., Banito, A., Chen, C.-W. D., Shroff, A., Tian, S., et al. (2023) · eLife · doi:10.7554/elife.80854 · Cited by 26 · see citing works

Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome

Shirahata‐Adachi, M., Iriyama, C., Tomita, A., Suzuki, Y., Shimada, K., & Kiyoi, H. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.015 · Cited by 24 · see citing works

Abstract PO-08: Understanding the properties and oncogenic mechanisms of EZH2 Y641 mutations in lymphoma

Nixon, S. J., Zimmerman, S. M., Simon, J. M., & Souroullas, G. P. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3249.lymphoma20-po-08 · Cited by 1 · see citing works

A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis

Berg, T., Thoene, S., Yap, D., Wee, T., Schoeler, N., Rosten, P., Lim, E. L., Bilenky, M., Mungall, A. J. J., Oellerich, T., et al. (2014) · Blood · doi:10.1182/blood-2012-12-473439 · Cited by 81 · see citing works

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

McCabe, M. T., Graves, A. P., Ganji, G., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Ott, H. M., Pappalardi, M. B., Allen, K. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116418109 · Cited by 493 · see citing works

Abstract 1057: Mutation of EZH2 A677 in human B-cell lymphoma promotes hyper-trimethylation of H3K27

McCabe, M. T., Graves, A. P., Ganji, G., Ott, H. M., Diaz, E., Halsey, W. S., Jiang, Y., Smitheman, K. N., Pappalardi, M. B., Allen, K. E., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-1057 · Cited by 1 · see citing works

Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model

Berg, T., Thoene, S., Yap, D., Wee, T., Schoeler, N., Rosten, P., Lim, E. L., Bilenky, M., Mungall, A. J. J., Oellerich, T., et al. (2013) · Blood · doi:10.1182/blood.v122.21.346.346